SGS Life Sciences Services to host 4th Antwerp Biopharm Seminar on clinical trial solutions

The one-day conference, entitled “Safety and Efficacy — Clinical Trials Solutions”, will bring together experts from SGS Life Services and the wider pharmaceutical industry, to discuss advances in biopharmaceutical research and development and combine a number of scientific talks, case studies and face-to-face meetings to highlight the most recent solutions in clinical development optimization.
SGS Life Science Services is to host a complimentary Biopharm Day in Antwerp, Belgium. The event, building on the success of previous years’ events, is to be held at the Lindner Hotel, on Thursday, 29 October 2015. The one-day conference, entitled “Safety and Efficacy — Clinical Trials Solutions”, will bring together experts from SGS Life Services and the wider pharmaceutical industry, to discuss advances in biopharmaceutical research and development and combine a number of scientific talks, case studies and face-to-face meetings to highlight the most recent solutions in clinical development optimization.
Joining SGS Life Science Services experts will be Ingeborg Heirman, Business Development Manager of VIB vzw, who will explain the role VIB plays in bridging academia with pharma/biotech companies and clinical research organizations, to further development of innovative drugs and biomarkers/diagnostic assays; Gary Kay, CEO of Cognitive Research Corporation, who will present on the 2015 FDA Draft Guidance on evaluating drug effects on driving; and Dr Jean François Rossignol, co-founder, Chief Scientific Officer and Chairman of Romark Laboratories, who will present a case study on influenza vaccine development. A tour of SGS Life Science Services’ Clinical Pharmacology Unit will be organized following the closing remarks. “The clinical research field has many challenges and opportunities which face both sponsors and service providers,” commented Jean-Luc Marsat, Business Manager at SGS Life Science Services. “By bringing together our clients and leading industry experts, and sharing experiences and knowledge in an open forum, we aim to give valuable insight into new trends and practices in biopharmaceutical research and development from a wide range of industry perspectives.”
Related News
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines. -
News Women in Pharma: Manufacturing personal and team success
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive... -
News Pfizer may shift production back to US under Trump pharma tariffs
At the 45th TD Cowen annual healthcare conference in Boston, USA, Pfizer CEO Albert Bourla outlined the potential for Pfizer to shift its overseas drug manufacturing back to the US as pharmaceutical industry players weigh their options against Presiden... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience. -
News Women in Pharma: Connecting accessible pharma packaging to patients – a Pharmapack Special
Throughout our Women in Pharma series, we aim to highlight how CPHI events encourage discussions around diversity, equity, and inclusion initiatives in the pharmaceutical industry. -
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries. -
News Trump administration halts global supply of HIV, malaria, tuberculosis drugs
In various memos circulated to the United States Agency for International Development (USAID), the Trump administration has demanded contractors and partners to immediately stop work in supplying lifesaving drugs for HIV, malaria, and tuberculosis to c... -
News 2024 Drug Approvals: a lexicon of notable drugs and clinical trials
50 drugs received FDA approval in 2024. The centre for biologics evaluation and research also identified six new Orphan drug approvals as under Biologics License Applications (BLAs). The following list picks out key approvals from the list, and highlig...
Recently Visited
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance